![gcs overview gcs overview](https://image.slidesharecdn.com/4eeb23d1-0ad0-480d-a3e7-31642c487342-151021065823-lva1-app6892/95/bilcare-gcs-overview-8-638.jpg)
in Biology from Fudan University in Shanghai, China.
![gcs overview gcs overview](https://image.slidesharecdn.com/gcs2009-123997611744-phpapp02/95/gcs-2009-overview-34-728.jpg)
in Molecular Biology from Arizona State University, and a B.S. in Biological Sciences from Columbia University, an M.S. in Finance and General Management and a Ph.D. Miao worked as a biotechnology equity analyst at JPMorgan and a research scientist at Roche. His career spanned financial, strategy and operational leadership positions including division CFO roles at Symrise, Schering-Plough and Pharmacia. Miao served as Executive Vice President and Chief Financial Officer, and held the additional role as interim Co-President and interim Co-Chief Executive Officer from September 2013 to September 2014, of Delcath Systems, Inc. From September 2011 to September 2014, Mr. (formerly known as PDI, Inc.), from October 2014 until March 2016. Miao served as Executive Vice President and Chief Financial Officer of Interpace Diagnostics, Inc. Miao served as a senior advisor to Pernix’s interim Chief Executive Officer and board of directors from May 2016 to July 2016. from July 2016 through December 2017, and served as a member of its board of directors from November 2016 to November 2017. Miao served as President and Chief Financial Officer of Pernix Therapeutics Holdings, Inc. Miao has over two decades of experience in global financial and business operations, capital markets, M&A and business development, and R&D for large multi-national and small to mid-market public and private companies in the healthcare, specialty chemicals and financial services industries. Graham Miao has served as our Executive Vice President and Chief Financial Officer since August 2018.
![gcs overview gcs overview](https://image.slidesharecdn.com/4eeb23d1-0ad0-480d-a3e7-31642c487342-151021065823-lva1-app6892/95/bilcare-gcs-overview-11-638.jpg)
Lewis first joined Pfizer in 1988 in the human health pharmaceutical segment and held positions of increasing responsibility in various commercial operations and general management roles. operations at Pfizer Animal Health, which he joined in 2007. Lewis previously served at Zoetis as president of international operations from 2015 to 2018 and as president of U.S. He most recently served as executive vice president and group president responsible for international operations, commercial development and global genetics at Zoetis Inc. Lewis has more than 30 years of experience in the life sciences space in national and international leadership roles. Clinton Lewis has served as our Chief Executive Officer and member of our Board since April 2021.